Introduction regulator of cell metabolism, growth, proliferation and survival (2) (3) (4) (5) (6) . Many cancerdriving mutations in genes encoding receptor tyrosine kinases, Ras, PI3K and PTEN stimulate cell proliferation, growth and survival through activation of mTOR kinase signaling. mTOR resides in two distinct multiprotein complexes called mTORC1 and mTORC2 (3) . mTORC1 directly phosphorylates ribosomal protein S6 kinase 1 (S6K1) and the eukaryotic translation initiation factor eIF4E-binding protein 1 (4E-BP1), both involved in protein translation (7) . The more recently discovered mTORC2
phosphorylates the survival kinase AKT on Ser 473, thus leading to activation of the AKT pathway, which drives several cancer-related cellular responses, including increased cell growth, proliferation and survival, increased cell migration and a shift to glycolytic metabolism (8) (9) (10) (11) (12) . Evidence also suggests that mTORC2 phosphorylates PKCα and regulates the organization of the actin cytoskeleton (9-10).
Rapamycin and rapamycin-related analogs (rapalogs) are allosteric inhibitors of mTORC1 (13, 14) . In addition to lacking a direct mTORC2 inhibitory effect, rapalogs do not inhibit the function of mTORC1 completely (15, 16) . Although rapalogs (e.g.
temsirolimus and everolimus) have demonstrated clinical benefits as single agents in a limited number of tumor types (e.g. renal cell carcinoma and mantle cell lymphoma), the mode of action of these drugs does not completely exploit the antitumor potential of fully inhibiting mTOR signaling (17) . The emerging role of mTORC2 in the activation of AKT in cancer is now considered important to tumor maintenance and progression, but this complex is generally resistant to rapalogs. In addition, inhibition of mTORC1 by rapamycin and its analogs has been shown to result in hyperactivation of AKT through the release of negative feedback loop between S6K1 and IRS-1 (18) . Indeed, Cloughesy et al have recently shown that hyperactivation of AKT following rapamycin treatment was associated with shorter time to progression in PTEN-deficient glioblastoma patients suggesting that TORC1-specific inhibition and associated AKT activation limits anticancer activity (19) . Consequently, intense efforts are now underway to develop inhibitors of the PI3K/AKT/mTOR pathway including ATP-competitive small molecule mTOR kinase inhibitors targeting both mTORC1 and mTORC2 (20) . Several recent reports have described biochemical and cellular properties of selective ATP-competitive inhibitors of mTORC1 and mTORC2 (21) (22) (23) (24) (25) (26) . These chemically distinct compounds all show suppression of both mTORC1-and mTORC2-mediated downstream signaling in various tumor cell lines. These inhibitors have been shown to induce a stronger suppression of protein synthesis and cell growth than rapamycin. More recently, anti-tumor activity and tumor pharmacodynamic effects were reported with the selective mTORC1 and mTORC2 inhibitors, AZD8055 and WYE-132.
In this report, we describe the preclinical characterization of OSI-027, an orally bioavailable, potent and specific dual inhibitor of mTORC1 and mTORC2. We demonstrate broad-spectrum anti-tumor activity in several xenograft models, in vivo differentiation from rapamycin, PK/PD/efficacy correlations in PI3K-wt vs. mutant models and tumor growth inhibition by intermittent and once weekly dosing schedules.
OSI-027 is currently in Phase I clinical development in cancer patients.
Materials and Methods

Synthesis of OSI-027 and OXA-01
OSI-027 is a 4,5,7-trisubstituted imidazo [5,1-f] triazine and OXA-01 is a 1,3,8-trisubstituted imidazo [1,5-a] pyrazine. These were synthesized by the methods described in patent application US-2007112005 (27) . Compound identity and purity (>99%) were verified by 1 H and 13 C nuclear magnetic resonance, mass spectrometry, and high performance liquid chromatography using Bruker Avance 400, Waters Micromass ZQ, and Waters LC module I Plus instruments, respectively as well as by elemental analysis.
OSI-027 was dissolved in DMSO at 10 mmol/L for use in biochemical or cellular in vitro assays. For in vivo studies, OSI-027 was dissolved in 20% Trappsol at an appropriate concentration to deliver the described dose in 10 mL/kg by oral gavage.
Cell Lines
Cancer cell lines were obtained from the American Type Culture Collection or other sources, as indicated in Supplementary Materials and Methods, banked after receipt, and passaged for < 6 months before use in experiments. All cell lines were cultured as directed. Rh1, Rh1mTORrr, Rh30, Rh30/mTORrr and Rh30/Rapa10K cells were grown in culture medium previously described (28) . centrifugation and 20 μg protein was loaded per well. Lysates were fractionated on 4-12% tris-glycine polyacrylamide gels and transferred to nitrocellulose membranes using a semidry apparatus. Membranes were blocked with 5% nonfat dry milk in Tris-buffered saline, and incubated overnight with primary antibody in 3% bovine serum albumin. The 
Animals
Female nu/nu CD-1 mice (6-8 weeks, 22-25 g) were purchased from Charles River Laboratories (Wilmington, MA) and allowed to acclimate for a minimum of one week prior to initiation of a study. Throughout the studies, animals were allowed sterile rodent chow and water ad libitum. All in vivo studies were conducted at OSI facilities with the 
Cell Proliferation Assays, Apoptosis Assays and Cell Cycle Analysis
For assays of cell proliferation, cells were seeded into 96-well plates and incubated for 3 days in the presence of OSI-027 or OXA-01 at various concentrations. Inhibition of cell growth was determined by luminescent quantification of intracellular ATP content using CellTiterGlo ® (Promega). Proliferation on Day 0 vs. 72h was used to plot dose-response curves for IC 50 calculations and to determine cell death. For apoptosis induction (Caspase3/7) assay, cells were seeded into 96-well plates and incubated for 48h in the presence of OSI-027 at various concentrations. Induction of caspase3/7 activity was determined by luminescent quantification using CaspaseGlo ® reagent (Promega). Fold induction of apoptosis was calculated as compared to DMSO-treated controls. For cell cycle analysis, cells were treated with DMSO, rapamycin or OSI-027 for 48h and stained with propidium iodide for analysis by flow cytometry (BD FACS Caliber). Percent of total cells in subG1, G0/G1, S and G2/M were calculated using FACS analysis software.
Pharmacokinetic Analysis
Blood from mice dosed with OSI-027 was collected in EDTA tubes and separated plasma was extracted by protein precipitation with methanol followed by centrifugation (10,000
x g for 10 minutes at 4°C). Extracted plasma samples were analyzed by high-performance liquid chromatography-tandem mass spectrometry. All pharmacokinetic parameters were obtained by non-compartmental analysis. glycerol, 50 mM, 150 mM NaCl, 1.5 mM MgCl 2 , 1 mM EDTA supplemented with fresh protease inhibitor cocktail (Sigma, MO), phosphatase inhibitor cocktail (Sigma, MO), 10 mM NaF and 1 mM sodium orthovanadate]. Tissue homogenates were clarified by centrifugation at 14,000g for 5 min at 4°C and supernatants were then analyzed by western blot as indicated. Plasma samples were also collected at specified time points for OSI-027 concentration analysis. Phopsho-4E-BP1 (T37/46), total 4E-BP1, Phospho-AKT (S473), total AKT or β-actin were quantified from western blots using Multi Gauge software program (FujiFilm). Ki67 nuclear staining was carried out using formalin-fixed, paraffin-embedded SKOV-3 xenografts. Ki67 immunohistochemical nuclear staining was quantified using ACIS II imager scoring ten fields.
In vivo
In vivo Anti-Tumor Efficacy Studies
Cells were harvested and implanted s.c. in the right flank of nu/nu CD-1 mice as described previously (29) . Tumors were allowed to establish to 200 ± 50 mm 
Results
OSI-027 is a Selective Inhibitor of mTORC1 and mTORC2
To establish the potency and selectivity of OSI-027 against mTOR and related kinases, native protein complexes were immunoprecipitated from HeLa cell lysates and assayed for inhibition of mTOR by OSI-027. The IC 50 value for OSI-027 was 4 nM (Supplementary Fig. S1 ). Immunoprecipitation with anti-Raptor antibodies to evaluate mTORC1 activity in the presence of drug, or anti-Rictor antibodies to assess mTORC2 activity indicated that OSI-027 is equipotent in the inhibition of both functional complexes. Greater than 100-fold selectivity was observed for mTOR relative to other PI3K-related kinases in biochemical assays. To determine the selectivity profile, OSI-027
(1 μM) was tested against 101 kinases using Caliper kinase profiling assays and the data are shown in Table S1 . None of those kinases were inhibited by >50%. In addition, OSI-027 activity was tested against 37 kinases at Invitrogen at 100 μM ATP and none of them were significantly inhibited (Supplementary Table S1 ). Additional selectivity data for OSI-027 in cell assays and an Ambit KinomeScan has been published recently by our colleagues (30) . These data indicate that OSI-027 is a potent and selective inhibitor of mTORC1/mTORC2.
OSI-027 Potently Inhibits mTORC1 and mTORC2 Activity in Cells
Structure of OSI-027, OXA-01 and rapamycin is shown in 
OSI-027 Inhibits 4E-BP1 and AKT Phosphorylation and Prevents Feedback to AKT in
Majority of Cancer Cell Lines
To survey the ability of OSI-027 to inhibit mTORC1-and mTORC2-mediated downstream signaling, we used western blot analysis to assess the inhibition of 4E-BP1 (T37/46) and AKT (S473) phosphorylation by OSI-027 (20 μM) and rapamycin (20 μM) after 24h treatment in 12 or 24 cancer cell lines representing various tumor types respectively. These concentrations were chosen based on the plasma exposure of OSI-027 at efficacious doses in preclinical models. OSI-027 significantly inhibited 4E-BP1 (T37/46) phosphorylation in the majority of cell lines tested and representative data are shown in Fig. 1C . In contrast, rapamycin failed to significantly inhibit p4E-BP1 in the majority of cell lines even at 20 μM, which is >200-fold higher than clinically relevant plasma concentrations. Moreover OSI-027 strongly inhibited pAKT (S473) in 83% of the 12 cell lines tested whereas rapamycin inhibited pAKT (S473) in only 13% of the 24 cell lines tested (Fig 1C and 1D ). More importantly, rapamycin stimulated pAKT (S473) in 62% of total 24 cell lines ( Fig. 1C and 1D ) or in 58% of same 12 cancer cell lines tested for OSI-027. These data suggest that OSI-027 can effectively inhibit pAKT and prevent feedback activation of AKT in the majority of tumor cell lines tested which stands in clear contrast to the observed effects of rapamycin. Further, OSI-027 inhibited IGF-1 induced pAKT (S473), while rapamycin was ineffective ( Supplementary Fig. S4 ). We also determined whether OSI-027 can inhibit pAKT (S473) induced by rapamycin treatment in the NCI-H23 NSCLC cell line and indeed, OSI-027 fully inhibited pAKT (S473) induced by rapamycin treatment (Fig. 1E) suggesting the likely role of mTORC2 activation in the stimulation of pAKT by rapamycin. Overall, these data suggest that OSI-027 can inhibit both mTORC1 and mTORC2 activity in the majority of tumor cell lines whereas rapamycin only inhibits mTORC1 and generally stimulates or has no effect on mTORC2-mediated signaling. Fig S5) Taken together, these data suggest that OSI-027 is superior to rapamycin in inhibiting cell proliferation and inducing cell death in a large panel of tumor cell lines. We further tested sensitivity to rapamycin and the mTORC1/mTORC2 inhibitor OXA-01 (a close analog of OSI-027) in parental Rh1 and an Rh1/mTORrr cell line in which S2035I mutation was introduced in FRB domain of mTOR to prevent rapamycin-FKBP12 binding. Rh1 cells are highly sensitive to rapamycin whereas Rh1/mTORrr cells show a decrease in rapamycin potency of at least 3 orders of magnitude (28) . In contrast to rapamycin both Rh1 and Rh1/mTORrr cells show similar sensitivity to the mTOR kinase inhibitor OXA-01 consistent with the direct action of this inhibitor on the mTOR catalytic protein rather than the FRB domain (Fig. 2C) . Similarly, OXA-01 inhibited proliferation of Rh30 rapamycin-sensitive parental), Rh30/mTORrr (FRB domain mutant) and Rh30/Rapa10K (selected in vitro for resistance to 10 μM rapamycin) cells with similar IC 50 values while rapamycin demonstrated a significant potency shift of >10000 fold ( Fig. 2C and 2D ). These data suggest that ATP-competitive Furthermore, these data predict that some patients with rapamycin-refractory cancers might still respond to mTOR kinase inhibitors such as OXA-01 or OSI-027.
OSI-027, But Not Rapamycin Strongly Induces Apoptosis in a PTEN-Null Cell Line
To study pro-apoptotic effects more directly, we next investigated whether OSI-027 and rapamycin can induce Caspase 3/7 activation in multiple cancer cell lines with or without PIK3CA or PTEN mutation. OSI-027 induced Caspase 3/7 activity by more than 2-fold in 3 out of 22 cell lines whereas rapamycin failed to induce Caspase 3/7 activity in all cell lines tested (Supplementary Table S3 ). Caspase 3/7 induction was concentrationdependent in IGR-OV1 and BT-474 cells (Fig. 3A) . Furthermore, we quantified sub-G1 cells following treatment with OSI-027 (20 μM), rapamycin (20 μM) or DMSO (control) (Fig 3B) . OSI-027, but not rapamycin, induced a significant sub-G1 fraction (40%) indicating apoptotic cell death (Fig 3B) . (Fig. 4A, Supplementary Fig. S7 ). At 24 hours postdose in the 65 mg/kg dose group, 47% inhibition of p4E-BP1 was still maintained with a corresponding plasma OSI-027 concentration of 2.2 μM. Such extended target suppression was associated with significant efficacy corresponding to 100% median tumor growth inhibition (TGI) in the MDA-MB 231 xenograft model (Fig. 4C) . In comparison, once daily administration of OSI-027 at 25 mg/kg for 14-days resulted in only moderate antitumor activity corresponding to 64% median inhibition of MDA-MB 231 tumor growth (TGI) compared to control vehicle treated animals for 14 days ( (Supplementary Fig S8) . These data suggest that sustained inhibition of tumor p4E-BP1 by more than 50% appears to be necessary for substantial tumor growth inhibition in this model. 
Pharmacodynamic Effects of OSI-
single 25 mg/kg dose, greater than 60% inhibition of tumor pAKT was observed for up to 4 hours with a rebound of pAKT content as drug plasma levels decreased ( Supplementary   Fig. S8 ). A single dose of 65 mg/kg resulted in marked inhibition (>50%) of pAKT for up to 16 hours with a rebound of pAKT content at 24 h (Fig. 4B) .
In vivo Antitumor Activity of OSI-027 and Rapamycin in Colorectal Tumors
The effects of OSI-027 were initially evaluated in the human colorectal xenograft models GEO and COLO 205, selected in part due to insensitivity to rapamycin in vitro (data not shown). In the COLO 205 tumor model, oral OSI-027 treatment at 65 mg/kg qd for 12 days resulted in 100% median TGI with 37% regression, whilst rapamycin treatment (20 mg/kg ip, d1-5, d8-12) resulted in 79% median TGI (Fig. 4D) . Statistical analysis showed significant difference between the efficacy of rapamycin and OSI-027 treatments (p<0.001). At the end of dosing, tumor samples were removed at 8 and 24 h and analyzed for phospho-S6, phospho-4E-BP1 and phospho-AKT. OSI-027 treatment resulted in significant inhibition of both mTORC1 and mTORC2 effectors at 8 h with recovery by 24 h (Fig. 4E and Suppl Fig S9) . The corresponding median plasma concentrations at 8 and 24 h were 22 and 0.77 μM, respectively. On the other hand, rapamycin treatment demonstrated sustained inhibition of only the mTORC1 effector pS6, but had little to no effect on mTORC2 signaling as assessed by tumor p4E-BP1 (T37/46) and pAKT (Ser473) (Fig. 4E and Supplementary Fig. S9 ). These data demonstrate that an mTORC1/mTORC2 specific inhibitor such as OSI-027 can achieve superior inhibitory effects on pAKT and p4E-BP1 in vivo as compared to an mTORC1-selective inhibitor such as rapamycin, and this inhibition of tumor pAKT and p4E-BP1 correlated with improved antitumor activity. 
Similarly, improved tumor growth inhibitory activity of OSI-027 was observed in the GEO xenograft model as compared to the efficacy of rapamycin (Fig. 4F) . Oral OSI-027 administration at 65 mg/kg qd for 14 days resulted in 95% median TGI, whilst rapamycin treatment (20 mg/kg ip, d1-5, d8-12) resulted in 75% median TGI (Fig 4F) .
Statistical analysis showed significant difference between the rapamycin and OSI-027 treatment groups (p<0.05).
Evaluation of In Vivo Efficacy of OSI-027 in mTOR Pathway Dependent Xenograft Models
The antitumor efficacy of OSI-027 was evaluated in PIK3CA mutant SKOV-3 and KRAS mutant OVCAR-5 human ovarian cancer xenograft models. In the SKOV-3 model, OSI-027 at 50 mg/kg qd for 14 days resulted in significant tumor growth inhibition (100% median TGI) with 15% regression. Additionally, twice daily dosing at 25 mg/kg bid corresponding to a total daily dose of 50 mg/kg resulted in comparable TGI (100% median TGI with 12% regression) (Fig. 5A) . In contrast, treatment of OVCAR-5 (KRAS mutant) tumors with 50 mg/kg qd or 25 mg/kg bid was only marginally efficacious showing 47% and 51% median TGI, respectively ( Figure 5C ). Further, to better understand the relationship between tumor growth inhibition and drug pharmacokinetics, continuous dosing of OSI-027 delivered via 14-day osmotic pumps was evaluated. In the OSI-027-sensitive tumor model SKOV-3 maintenance of a steady state concentration of approximately 0.5 μM for 14 days was sufficient to achieve maximal efficacy equivalent to 50 mg/kg qd dosing (100% median TGI with 20% regression) (Fig. 5A) . Figure 5B shows the actual plasma drug concentration on days 5 and 13 for estimated 0. sensitive to OSI-027, a higher steady state plasma concentration of 6 μM was necessary to achieve efficacy equivalent to 50 mg/kg qd dosing (Fig. 5C ). Steady-state concentrations of 0.5 and 2 μM were inactive in this model (data not shown).
Pharmacodynamic evaluation in additional OVCAR-5 tumor-bearing mice on day 11 of treatment demonstrated that tumor phospho-4E-BP1 inhibition in tumor samples was achieved only at 6 μM steady state ( Figure 5D ) and this pharmacodynamic inhibition correlated with efficacy ( Figure 5C ). We further evaluated the effects of intermittent dosing of OSI-027 in the PTEN null IGR-OV1 ovarian carcinoma xenograft model. OSI-027 administration at 50 mg/kg qd for 14 days resulted in 100% TGI ( Figure 5E ).
OSI-027 administration at 150 mg/kg q3d x 5 doses, corresponding to the same cumulative dose of 50 mg/kg per day, resulted in equivalent tumor growth inhibition (100% median TGI with 17% regression). Similarly, a high intermittent dose of 300 mg/kg administered once weekly resulted in comparable efficacy (100% TGI with 45% regression). Similar results were observed with the SKOV-3 model (data not shown). Pharmacokinetic analysis at the 300 mg/kg dose showed that >20 μM OSI-027 plasma concentrations were maintained for at least 96 h, with a decline to 0.58 μM by 120 h. Finally, we determined the level of proliferation in SKOV-3 tumors by staining tumor samples for Ki67. OSI-027 was administered at 65 mg/kg qd for 3 days and tumor samples were collected 8 h post last dose. OSI-027 treatment resulted in 51.8 ± 4.2% inhibition of Ki67 staining compared to vehicle-treated control tumors (Fig 5F) confirming the anti-proliferative effects of OSI-027. (Table   1) . In all studies, OSI-027 was well tolerated with <10% body weight loss observed during the treatment period.
Discussion
Clinical studies with rapamycin and rapalogs have validated mTOR as an anticancer target. However, the effectiveness of rapalogs may be limited by lack of inhibition of mTORC2 signaling functions and activation of AKT via release of the S6K-IRS-1 negative feedback loop. These considerations led to intensive efforts to develop mTOR-selective kinase inhibitors that completely suppress both mTORC1 and mTORC2 activities in cancer cells. In this report, we provide biochemical, cellular and in vivo evidence that OSI-027 is a potent and selective dual inhibitor of mTORC1 and mTORC2, and is mechanistically and functionally distinct from rapamycin. wild-type (OVCAR-5) xenograft models indicates that PIK3CA mutant models are more sensitive to OSI-027 treatment. Interestingly, in a PTEN-null IGR-OV1 model, a dose of mg/kg. This efficacy was attributed to sustained plasma drug concentrations greater than 20 μM for at least 4 days after dosing. Taken together, these data suggest that in sensitive tumors, maintenance of trough drug concentrations of 0.5 μM achieved through daily or intermittent oral dosing are needed for therapeutic efficacy. The efficacy of OSI-027 and rapamycin was compared in GEO and COLO 205 colorectal cancer xenografts dosing both agents at MTD, with rapamycin dosed i.p to compensate for its poor oral bioavailability. In these studies, OSI-027 induced significantly greater tumor growth inhibition than rapamycin. Interestingly, both of these cell lines have an active IGF-II/IGF-1R autocrine loop thereby activating the PI3K/AKT pathway. The limited efficacy of rapamycin compared to OSI-027 in these models is likely to be due to the fact that OSI-027 inhibits both mTORC1 and mTORC2 while rapamycin only inhibits mTORC1. In all (>10) in vivo xenografts tested, the efficacy of OSI-027 was not restricted to PTEN deficiency, PIK3CA mutation or PTEN mutation status. Table 1 . Broad-spectrum anti-tumor activity of OSI-027
OSI-027 was administered orally once daily at indicated dose for 14 days. % tumor growth inhibition and % regression were calculated as described in 'materials and methods' section. N=8 animals/group in all studies. 
